1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Tevogen received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market. With this and a prior September 9, 2026 notice on publicly held shares, both Nasdaq compliance matters are now closed, removing the listing deficiency concerns the company had previously disclosed.
Nasdaq notice dated September 29, 2026 confirmed compliance with the $50 million minimum market value of listed securities requirement (Rule 5450(b)(2)(A))
Earlier notice dated September 9, 2026 confirmed compliance with the minimum market value of publicly held shares requirement (Rules 5450(b)(2)(C) and 5450(b)(3)(C))
Company issued a press release on September 30, 2026, furnished as Exhibit 99.1
Outlook Therapeutics received a Nasdaq notice on September 25, 2026, stating its stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, but the company has until March 24, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.
Nasdaq notice dated September 25, 2026 cites a closing bid below $1.00 for 30 consecutive business days under Listing Rule 5550(a)(2)
Compliance Date is March 24, 2027, 180 calendar days under Rule 5810(c)(3)(A)
Company may be eligible for a second 180-day period and may need a reverse stock split; if not compliant, Nasdaq would issue a delisting notice that the company could appeal
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
MoonLake Immunotherapeutics said it submitted a Biologics License Application to the U.S. Food and Drug Administration on September 30, 2026, seeking approval of its tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 years and older. The filing marks a regulatory step toward a possible approval, but the FDA has not yet decided whether to accept the application for review.
BLA submitted to the FDA on September 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa
FDA acceptance decision expected within approximately 60 days of submission
Planned review timeline expected from the FDA within approximately 74 days of submission
ChargePoint entered a settlement term sheet on September 28, 2026 to resolve the Farooq Khan securities class action in federal court in Northern District of California. The company will pay a $11 million cash settlement, which requires Court approval, and the company denies any wrongdoing.
Cash settlement payment of $11,000,000, to be placed in escrow within 21 days after the later of preliminary Court approval or receipt of payment instructions
Company expects to sign a final Settlement Agreement and seek preliminary approval within 30 calendar days of signing the term sheet
Settlement would resolve claims against the company and former CEO Pasquale Romano, former CFO Rex Jackson, and former Chief Commercial and Revenue Officer Michael Hughes, if approved
All In FutureTech Alliance disclosed that counsel for stockholder Primo Vital Limited sent letters in May and September 2026 claiming that its prior beneficial ownership disclosures about director Jingsheng (Jason) Lu were inaccurate. The company says it takes no position on the dispute over 11,986,523 shares it reported as roughly 31.3% of its common stock, and that this report does not resolve who controlled those shares.
Primo Letters dated May 22, 2026 and September 2, 2026 claim Mr. Lu was removed as Primo's director on May 19, 2026 and lost authority on March 3, 2026, when Ourgame was placed into liquidation in the Cayman Islands.
The company's Form 10-K and Special Meeting Proxy Statement reported Primo as record holder of 11,986,523 shares, about 31.3% of common stock, with shared voting power held by Mr. Lu.
The company relied on a December 11, 2024 joint Schedule 13D/A and says it will evaluate further information and its disclosure obligations.
AEON Biopharma received official minutes from its FDA Type 2b meeting on the development path for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with the company's two-stage pharmacodynamic study design and said previously completed Daewoong comparative studies may be submitted as supportive evidence, while the company will not start a standalone comparative efficacy study for now. The filing also says the Two-Year Milestone Warrants will expire on November 16, 2026, which affects warrant holders.
FDA agreed in principle with the two-stage CMAP pharmacodynamic study design; company expects to file an IND in Q4 2026 and start the study in Q1 2027
Previously completed Daewoong comparative studies may be considered as supportive evidence, subject to scientific bridging
No standalone comparative efficacy study planned at this time; company plans to return to the FDA in 2027
Two-Year Milestone Warrants will expire on November 16, 2026, unless exercised before that date
DBV Technologies said it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its VIASKIN Peanut Patch in children with peanut allergy aged 4 through 7 years, and has requested Priority Review. The application is supported by results from the Phase 3 VITESSE trial, which enrolled 654 children, and the FDA previously granted the patch Breakthrough Therapy Designation. The filing reports a regulatory milestone, not revenue or approval, and the company states the product has not been authorized for sale in any country.
BLA submitted to the FDA for VIASKIN Peanut Patch in children aged 4 through 7 years, announced September 29, 2026
DBV has requested Priority Review; the FDA previously granted Breakthrough Therapy Designation
VITESSE Phase 3 trial enrolled 654 children, randomized 2:1 to active patch or placebo
The company states the product has not been authorized for sale in any country
Meridian Holdings disclosed a September 25, 2026 provisional measure signed by Brazil's President that bans operating, intermediating and advertising online betting and online casino services in Brazil and requires funds to be returned to bettors. The company says Brazil is an immaterial share of Group revenue and that its exposure is limited because it did not commit large marketing spending before licensing, but the filing gives no dollar figures for the affected business.
Brazil's President signed the Provisional Measure on September 25, 2026, prohibiting online betting and online casino operation, intermediation and advertising in Brazil.
The measure requires that funds be returned to bettors.
The company says Brazil is an immaterial share of Group revenue and does not quantify the exposure.
Subsidiary Meridian Gaming Brasil SPE Ltda's authorization runs until December 31, 2029, and the measure must be approved by the Brazilian Congress within 120 days of adoption to remain in effect.
Maison Solutions Inc. said on September 23, 2026 that Nasdaq notified it of noncompliance with Listing Rule 5250(c)(1) because its quarterly report for the quarter ended July 31, 2026 was not filed on time and its annual report for the fiscal year ended April 30, 2026 remains delinquent. The notice has no immediate effect on the listing, but the company must submit a compliance plan by October 19, 2026, and Nasdaq may grant an exception until February 9, 2027 if it accepts the plan.
Nasdaq letter received September 23, 2026 cites late Form 10-Q for the quarter ended July 31, 2026 and delinquent Form 10-K for the fiscal year ended April 30, 2026
Compliance plan due to Nasdaq by October 19, 2026, a deadline set in an earlier August 20, 2026 notice
If Nasdaq accepts the plan, the exception could run to February 9, 2027; if not, the company may appeal to a Nasdaq Hearings Panel
Class A common stock continues to trade on The Nasdaq Capital Market under the symbol MSS
Nasdaq has determined that Liminatus Pharma regained compliance with its minimum bid price rule and closed the matter, according to an 8-K filed September 29, 2026. The company had transferred to The Nasdaq Capital Market effective August 4, 2026, after a hearing before the Nasdaq Hearings Panel, and completed a 1-for-50 reverse stock split on August 20, 2026. Its closing bid price was above $1.00 for 13 consecutive trading days, from August 21 to September 9, 2026.
Nasdaq notice dated September 24, 2026 said the company regained compliance with the Bid Price Rule and the matter is closed.
Closing bid price was above $1.00 for 13 consecutive trading days, August 21 to September 9, 2026.
The company effected a 1-for-50 reverse stock split at the close of trading on August 20, 2026.
Company issued a press release on September 29, 2026 (Exhibit 99.1) announcing the regained compliance.
SurgePays received a Nasdaq letter granting an additional 180-day period, to March 22, 2027, to regain compliance with the $1.00 minimum bid price requirement. Nasdaq also said the company now meets the stockholders' equity requirement, but could face delisting if it fails to show compliance with continued listing criteria in its next periodic report.
Nasdaq granted an additional 180-calendar-day period, ending March 22, 2027, to regain the $1.00 minimum bid price.
The initial compliance period expired September 21, 2026, after Nasdaq first flagged the deficiency on March 23, 2026.
Nasdaq separately determined the company complies with the stockholders' equity requirement, addressing its March 18, 2026 letter.
If the company does not regain compliance by March 22, 2027, Nasdaq will issue a delisting notice; the company has said it may reverse split if necessary.
Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate (OLC) on September 29, 2026, with chemistry and manufacturing data from a new third-party drug product vendor. The company expects FDA acceptance within 30 days and a new PDUFA date six months from resubmission, following a June 2026 Complete Response Letter. The company also appointed Meredith S. Manning as an independent director effective October 1, 2026.
NDA resubmitted September 29, 2026, including CMC data from a new third-party drug product manufacturing vendor and 12 months of OLC drug product stability data.
Company anticipates FDA acceptance within 30 days; new PDUFA date expected six months from resubmission.
June 2026 CRL cited the same third-party manufacturing deficiencies as the June 2025 CRL; the original vendor's FDA inspection had not occurred as of September 29, 2026.
Meredith S. Manning appointed independent director effective October 1, 2026; cash, equivalents and marketable securities were $61.4 million as of June 30, 2026.
Aldeyra Therapeutics said it intends to submit a Formal Dispute Resolution Request to the FDA, appealing the March 16, 2026 Complete Response Letter that denied approval of reproxalap for dry eye disease. The company also extended its projected operational cash runway into 2029, based on $45.1 million in cash and cash equivalents as of June 30, 2026. The appeal's outcome and timing remain uncertain, and the filing states that the FDRR submission and meeting with the Office of New Drugs are expected in the fourth quarter of 2026.
Intends to submit an FDRR to the FDA's Office of New Drugs, appealing the March 16, 2026 Complete Response Letter for reproxalap
FDRR submission and a meeting with the Office of New Drugs are expected in the fourth quarter of 2026
Cash and cash equivalents were $45.1 million as of June 30, 2026; operational cash runway extended into 2029
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Panel granted continued listing in a notice received September 25, 2026.
Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
Filing states there can be no assurance the company will meet the conditions.
Unicycive Therapeutics disclosed that a securities class action was filed on September 3, 2026, in the U.S. District Court for the Northern District of California against the company and certain officers. The suit alleges violations of federal securities laws tied to public statements about the company's new drug application for oxylanthanum carbonate phosphate binder. The company says the claims are meritless and plans to defend the lawsuit vigorously, but the filing does not state any financial impact.
Class action filed September 3, 2026, in U.S. District Court for the Northern District of California
Suit names the company and certain officers and alleges federal securities law violations
Allegations relate to public statements about the new drug application for oxylanthanum carbonate phosphate binder for hyperphosphatemia in dialysis patients with chronic kidney disease
Company says the claims are meritless and intends to vigorously defend
Gossamer Bio received a Nasdaq letter on September 25, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had completed a 1-for-80 reverse stock split on September 10, 2026, with split-adjusted trading beginning September 11, 2026. The filing shows the listing issue is resolved, but it does not report any change to financial results.
Nasdaq letter dated September 25, 2026 confirms compliance with the minimum bid price rule under Nasdaq Listing Rule 5450(a)(1)
The matter followed a Nasdaq letter received April 8, 2026, after the stock failed to trade at $1.00 or more for 30 consecutive business days
1-for-80 reverse stock split effective September 10, 2026; split-adjusted trading began September 11, 2026
CapsoVision said the U.S. Food and Drug Administration cleared AI Highlights, an AI-assisted reading feature for its CapsoCam Plus capsule endoscopy system, on September 25, 2026. The company announced the clearance on September 28, 2026, and the filing contains no revenue, profit, or guidance figures, so its direct financial effect on shareholders is not quantified.
FDA clearance received September 25, 2026; announced September 28, 2026
Tool flags suspected abnormal lesions in small bowel capsule studies to reduce physician review time
Intended for adult and pediatric patients over two years old with suspected small bowel bleeding; does not replace gastroenterologists' diagnosis
A federal jury awarded Ramaco Resources' subsidiary $30.0 million in damages on September 25, 2026, in its lawsuit against Federal Insurance Company and ACE American Insurance Company over a denied claim for a 2018 silo failure at the Elk Creek plant. The court entered judgment on the verdict, but attorneys' fees remain to be decided and the defendants may still challenge the award through post-trial motions or an appeal.
Jury awarded $27.5 million for net economic loss and $2.5 million for aggravation and inconvenience.
Judgment was entered on September 25, 2026, against Federal Insurance Company and ACE American Insurance Company.
Attorneys' fees were not decided by the jury and will be determined by the Court.
Defendants may file post-trial motions within 28 days of judgment and a notice of appeal within 30 days of the final judgment.
After the market close on September 25, 2026, a jury awarded $5.7 billion in damages to the plaintiff in Taction Technology, Inc. v. Apple Inc., a case in which Burford has a financial entitlement. Burford says that if the verdict were paid as is, its entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds, but the amount is likely to change in post-trial and appellate proceedings. For shareholders, the verdict is not a final judgment or cash received, and Burford warns it could recover substantially less or incur a total loss.
Jury verdict of $5.7 billion in damages, announced in a release dated September 28, 2026, after the market close on Friday, September 25, 2026
If paid as is, Burford's entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds
Apple has filed a motion for judgment as a matter of law, and the Federal Circuit will scrutinize large verdicts on appeal
Burford states that it could recover substantially less than the verdict amount or, in certain circumstances, incur a total loss
GEE Group's audit committee is conducting an independent inquiry into an Executive Employment Agreement dated April 27, 2023 with Allison Dewan, the daughter of Chairman and CEO Derek Dewan, who is named Vice President of Corporate Development. The agreement and its terms had not previously been disclosed in SEC filings, and the committee is reviewing its origin, authorization, related disclosure controls, and whether it should have been disclosed as a related party transaction.
Agreement dated April 27, 2023 names Allison Dewan Vice President of Corporate Development
Initial base salary of $110,000 per year, with a five-year term ending April 26, 2028
Audit committee is reviewing whether the agreement should have been disclosed as a related party transaction, given compensation above $120,000
Filing signed by CFO Kim Thorpe on September 28, 2026
Southland Holdings received a notice from NYSE American on September 23, 2026, saying it is not in compliance with stockholders' equity listing standards after reporting a $248.2 million stockholders' deficit at June 30, 2026. The shares and warrants remain listed for now, but the company must submit a compliance plan by October 23, 2026, and regain compliance by March 23, 2028, or face delisting proceedings.
NYSE American notice received September 23, 2026, citing Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide
Stockholders' deficit of $248.2 million at June 30, 2026; company reported net losses in its last three fiscal years
Compliance plan due October 23, 2026; compliance deadline March 23, 2028
Shares (SLND) and warrants (SLND WS) continue trading on NYSE American for now
Dyadic International received two Nasdaq deficiency notices on September 25, 2026: one for its stock trading below the $1 minimum bid price for 30 consecutive business days, and one for its market value of listed securities falling below $35 million over the same period. Both notices have no immediate effect on the common stock's listing on the Nasdaq Capital Market, but the company must regain compliance by March 24, 2027 or face delisting notice.
Bid price below $1 per share for the last 30 consecutive business days under Nasdaq Rule 5550(a)(2)
Market value of listed securities below the $35 million minimum for the last 30 consecutive business days under Rule 5550(b)(2)
Compliance Date is March 24, 2027, requiring 10 consecutive business days at or above the thresholds
Company may appeal any delisting determination to a Nasdaq hearings panel, with no assurance of success
Nasdaq notified Fusemachines on September 24, 2026 that its securities are subject to delisting because it did not meet the $50,000,000 minimum market value of listed securities as of September 23, 2026, the deadline for regaining compliance. The company plans to request a hearing before a Nasdaq Hearings Panel, which would pause delisting action, but the filing says there is no assurance the panel will grant continued listing or that the company will regain compliance.
Nasdaq first notified the company on March 27, 2026 that it no longer met the $50,000,000 MVLS requirement
Compliance deadline was September 23, 2026; Nasdaq said the company remained non-compliant as of that date
Company plans to timely request a hearing before the Nasdaq Hearings Panel, which would stay delisting action until the hearing and any panel extension expire
Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, saying it does not meet the $4.0 million stockholders' equity requirement, as it reported $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, and regain compliance by March 21, 2028, or face delisting proceedings, which raises the risk of delisting for shareholders.
Stockholders' equity was $3.1 million as of June 30, 2026, below the $4.0 million NYSE American requires for companies with net losses in three of four recent fiscal years
Notice received September 21, 2026; plan of compliance due October 21, 2026
Company must regain compliance by March 21, 2028; delisting proceedings begin if no plan is submitted or accepted
Common stock continues to trade as CLDI with a ".BC" designation for noncompliance
Future Money Acquisition Corp (Nasdaq: FMAC) received a Nasdaq deficiency letter on September 22, 2026, because it has not yet filed its Form 10-Q for the quarter ended July 31, 2026. The notice has no immediate effect on the listing or trading of the company's securities, but the company must submit a plan to regain compliance by November 23, 2026, and the company says it cannot assure that Nasdaq will accept the plan or grant an exception.
Nasdaq notice dated September 22, 2026, cites Listing Rule 5250(c)(1) on timely periodic reports
Form 10-Q for the fiscal quarter ended July 31, 2026, has not been filed
Company must submit a compliance plan by November 23, 2026
If the plan is accepted, Nasdaq may allow an exception until March 22, 2027
Netcapital Inc. received a Nasdaq notice on September 21, 2026, saying it is not in compliance with the rule requiring timely periodic reports because it has not filed its quarterly report for the period ended July 31, 2026, and remains delinquent on its annual report for the fiscal year ended April 30, 2026. The notice has no immediate effect on the stock, which continues to trade on the Nasdaq Capital Market as NCPL, but the company must submit a compliance plan by October 23, 2026, and there is no assurance Nasdaq will accept it.
Nasdaq notice received September 21, 2026, citing Listing Rule 5250(c)(1)
Company must submit a plan to regain compliance by October 23, 2026
If accepted, Nasdaq may allow an exception until February 9, 2027; if not, the company can appeal to a Nasdaq Hearings Panel
Stock continues to trade on the Nasdaq Capital Market under NCPL for now
SANUWAVE Health received a Nasdaq notice on September 23, 2026, because its Market Value of Listed Securities was below $50 million for 30 consecutive business days, the minimum for continued listing on The Nasdaq Global Market. The notice has no immediate effect on the listing, but if the company does not regain compliance by March 22, 2027, it will receive a delisting notice, and the company cannot guarantee it will keep its listing.
Nasdaq notice received September 23, 2026, citing Listing Rule 5450(b)(2)(A)
Company must close at or above $50 million MVLS for 10 consecutive business days to regain compliance
Compliance period runs 180 calendar days from the notice, until March 22, 2027
Company may consider transferring to The Nasdaq Capital Market if it meets that market's requirements
NextCure filed a petition on September 14, 2026 in the Delaware Court of Chancery asking the court to validate its July 2025 reverse split and the shares issued in reliance on it. The company says a 2026 change to Delaware law creates uncertainty over whether a higher supermajority vote standard should have applied to the 2025 approval, which could affect its pending business combination with Avere Therapeutics and its capitalization. The filing describes the court hearing as the venue where the uncertainty will be addressed.
Petition filed September 14, 2026 under Section 205 of the Delaware General Corporation Law; the court ordered notice to stockholders on September 21, 2026.
The 2025 reverse split amendment received about 89.92% of votes cast and about 64.76% of outstanding shares, short of the 66 2/3% supermajority standard in the charter.
Hearing set for 3:00 p.m. Eastern Time on November 6, 2026 in Wilmington, Delaware.
Stockholders wishing to oppose the petition must file a written submission by October 27, 2026, or appear at the hearing.
GT Biopharma received notice from Nasdaq on September 22, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's common stock maintained a closing bid price above $1.00 for at least ten consecutive business days, which Nasdaq required. The regained compliance removes the risk of delisting that the company had faced under the earlier deadline of November 16, 2026.
Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the minimum bid price requirement.
The stock had closed below $1.00 for 30 consecutive business days, leading to a Nasdaq notice on November 20, 2025.
On May 20, 2026, Nasdaq granted an additional 180 calendar day compliance period, through November 16, 2026.
The company's common stock closed above $1.00 for at least ten consecutive business days to meet the standard.
Nektar Therapeutics disclosed that a federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in their license agreement for rezpegaldesleukin. The jury awarded Nektar $90 million in damages plus interest, to be determined by the court. The verdict remains subject to post-trial proceedings and possible appeal, so the amount Nektar ultimately receives is not yet certain.
Jury verdict returned September 24, 2026 in Nektar Therapeutics v. Eli Lilly & Co., Case No. 3:23-cv-03943-JD
Jury awarded Nektar $90 million in damages plus interest, with interest to be set by the District Court
Verdict is subject to post-trial proceedings and any resulting judgment may be appealed
Beasley Broadcast Group disclosed that board member Peter A. Bordes, Jr. died on September 19, 2026, leaving its Audit Committee with two members and below Nasdaq's three-member requirement. The company said it notified Nasdaq and intends to use a cure period, which ends at the earlier of its next annual stockholder meeting or September 19, 2027, and plans to appoint an independent director to the committee.
Director Peter A. Bordes, Jr. died on September 19, 2026; he served on the Audit and Compensation Committees.
Audit Committee now has two members, below the three required by Nasdaq Rule 5605(c)(2)(A).
Company notified Nasdaq after receiving notice on September 23, 2026 and intends to rely on the cure period.
Cure period expires at the earlier of the next annual meeting or September 19, 2027.
SCWorx received a Nasdaq Hearings Panel decision to delist its common stock, which has been suspended from Nasdaq since April 14, 2026, and now trades on the OTCQB. The company says a September 16, 2026 private placement cured its publicly held shares deficiency and has asked the Panel to reconsider, but the Panel has not yet acted, and the outcome is uncertain for shareholders.
Nasdaq Hearings Panel decided on September 17, 2026 to delist the common stock; the company requested reconsideration on September 18, 2026.
The company says the private placement and related share issuances give it more than 500,000 publicly held shares, meeting the Publicly Held Shares Rule.
To regain Bid Price Rule compliance, the stock must close at or above $1.00 for 10 consecutive trading days on or before October 5, 2026.
If all purchasers terminate, the company would return an aggregate of $938,000 and cancel 350,000 shares and warrants; the deadline for termination notices is October 15, 2026.
Sarepta Therapeutics entered a settlement agreement with REGENXBIO, the Trustees of the University of Pennsylvania and Catalent to resolve pending patent infringement litigation and an related appeal over several patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million, an amount it had already recorded as a litigation contingency charge in the second quarter of 2026. The settlement releases Sarepta from past infringement claims and includes covenants not to sue for ELEVIDYS and other AAVrh74-based products, which removes a source of legal uncertainty for shareholders.
Sarepta will pay REGENXBIO a $39.0 million lump sum within ten days of the September 23, 2026 Effective Date.
The $39.0 million matches a litigation contingency charge recorded in the three and six months ended June 30, 2026.
REGENXBIO and UPenn released claims up to the Effective Date and agreed not to sue over ELEVIDYS and other AAVrh74-based products under the UPenn Patents.
The Litigations will be dismissed with prejudice, and the settlement includes no admission of liability.
Gossamer Bio said it submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension, its first NDA. The application relies on the Phase 3 PROSERA study as one adequate and well-controlled investigation, supported by the Phase 2 TORREY study. The FDA has not yet decided whether to accept the application for filing, which the company expects could happen later this year.
NDA for seralutinib in PAH submitted to the FDA in September 2026, the company's first NDA
Submission follows a Pre-NDA Type B meeting with the FDA in June 2026 and the FDA's written meeting minutes
FDA will decide whether to accept the NDA for filing after its initial review, which the company anticipates could occur later this year
REGENXBIO and the University of Pennsylvania agreed to settle patent infringement litigation with Sarepta Therapeutics and Catalent over Sarepta's ELEVIDYS gene therapy. Sarepta will pay REGENXBIO $39.0 million within 10 days of the settlement's effective date, and the parties will end the ongoing patent litigation.
Sarepta will pay $39.0 million to REGENXBIO within 10 days of the settlement's effective date.
The settlement covers U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to SRP-9001 (ELEVIDYS).
REGENXBIO and UPenn release current infringement claims and agree to a covenant not to sue for future claims on AAVrh74-based Sarepta gene therapy products.
The full agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Greenland Technologies Holding Corporation received a Nasdaq letter on September 22, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement. The company's Class A ordinary shares closed at $1.00 or above for 10 consecutive business days from September 8 through September 21, 2026, and Nasdaq has closed the matter. For shareholders, this removes the risk of delisting over the bid price issue.
Nasdaq notified the company on March 12, 2026 that its Class A ordinary shares had closed below $1.00 for 30 consecutive business days
On September 10, 2026, Nasdaq granted an additional 180-day period, to March 8, 2027, to regain compliance
On September 22, 2026, Nasdaq confirmed compliance after 10 consecutive business days at or above $1.00, from September 8 through September 21, 2026
Nasdaq approved Lakeshore Acquisition III Corp.'s application to move the listing of its units, ordinary shares and rights from the Nasdaq Global Market to the Nasdaq Capital Market. The company's securities will keep trading under the existing symbols, and Nasdaq says the Capital Market operates in substantially the same manner, though listed companies must still meet its financial and governance requirements.
Nasdaq approval received on September 22, 2026
Transfer to Nasdaq Capital Market takes effect at market open on September 24, 2026
CytoSorbents said it regained compliance with Nasdaq's $1.00 minimum bid price requirement after its closing bid price was at or above $1.00 for 10 consecutive trading sessions ending September 21, 2026, and Nasdaq closed that matter on September 22, 2026. The company still has not met Nasdaq's $35 million minimum market value of listed securities requirement, which it must meet by December 28, 2026, or it will receive a delisting notice, and the company states there is no assurance it will maintain its Nasdaq listing.
Nasdaq notified the company on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement and closed the matter.
The company must have listed securities worth at least $35 million for 10 consecutive business days by December 28, 2026 to regain compliance with the market value requirement.
The company is evaluating actions and may consider increasing stockholders' equity to at least $2.5 million.
If the company does not regain compliance by December 28, 2026, it will receive a delisting notice and may appeal.
Astrana Health said social engineering attacks, in which threat actors impersonated company personnel and spoofed its main phone number, led to unauthorized activity in its environment. The company has determined the incident is material and believes certain private or confidential information was accessed or acquired, but the full scope remains under investigation. The company currently does not expect a material effect on its financial condition and results of operations, though it cannot yet estimate the full impact.
Company determined the incident is material as of September 22, 2026, citing the potential confidential and sensitive nature of the data involved.
Threat actors impersonated Company personnel and spoofed the main corporate telephone number to contact employees seeking unauthorized system access.
Company engaged a third-party forensics firm, notified law enforcement, and is notifying state and federal regulators and payer partners.
Company maintains cybersecurity insurance but says coverage may not be sufficient to cover all losses.
Reborn Coffee received a Nasdaq notice on September 16, 2026, saying it no longer meets the minimum $2,500,000 stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company reported stockholders' equity of $735,642 in its June 30, 2026 Form 10-Q, and it must submit a plan to regain compliance by November 2, 2026. The notice has no immediate effect on the listing, but the company states there is no assurance its plan will be accepted, and a rejected plan could lead to an appeal to a Nasdaq Hearings Panel.
On September 16, 2026, Nasdaq notified the company that its reported stockholders' equity of $735,642 is below the $2,500,000 minimum under Listing Rule 5550(b)(1).
The company also does not meet Nasdaq's alternative standards for market value of listed securities or net income from continuing operations.
A plan to regain compliance is due by November 2, 2026; if accepted, Nasdaq can grant up to 180 calendar days to regain compliance.
A separate Nasdaq notice about the late June 30, 2026 Form 10-Q was closed on September 16, 2026, after the company filed the report on September 14, 2026.
Idaho Copper received a U.S. Forest Service letter approving its Exploration Plan of Operations and 2026 annual operating plan for the CuMo project in Boise County, Idaho, clearing the way for drilling and road-building. The company says the approval removes the remaining administrative conditions and lets it start work, with up to 15,000 feet of diamond core drilling targeted this season.
Forest Service letter approving the Exploration Plan of Operations and 2026 annual operating plan; USFS accepted the company's reclamation surety bond on or before the letter date
USFS accepted the signed Forest Service Evaluation form on September 9, 2026
Company is targeting up to 15,000 feet of additional diamond core drilling this season, with a larger campaign planned for 2027 toward a Prefeasibility Study
Compass Therapeutics said the FDA recommended it conduct a trial demonstrating a survival benefit before submitting a Biologics License Application for tovecimig in previously treated advanced biliary tract cancer. The company said it does not believe a new trial is warranted before submission and will keep engaging with the FDA, which means the timing and path to approval are now uncertain.
FDA recommended a trial demonstrating a survival benefit before a BLA submission for tovecimig
Phase 2/3 COMPANION-002 showed ORR of 18.0% vs. 5.3% with paclitaxel alone (p=0.0228)
Median progression-free survival was 4.7 vs. 2.6 months, hazard ratio 0.44 (p<0.0001)
Overall survival analyses did not reach statistical significance due to crossover
The FDA has lifted the full clinical hold on Filana Therapeutics' IND for a planned Phase 2a study of simufilam in TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027, so the hold removal is a development milestone rather than a change in financial results.
FDA lifted the full clinical hold on the simufilam IND, announced September 22, 2026
Planned Phase 2a study: 16-week randomized, double-blind trial at 13 U.S. sites, targeting 40 subjects aged 12 to 55
Patient screening expected to begin by the first quarter of 2027
Company completed trial-readiness work during the hold, including engaging a clinical research organization and identifying sites
The European Commission granted marketing authorization for Ubeslo and Evlarco, obicetrapib-based treatments for primary hypercholesterolaemia or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide. The company's partner Menarini holds European commercialization rights, and the approvals trigger milestone payments in the mid-teens of millions of euros, with up to an additional €833 million available on future milestones.
Approvals cover all EU Member States, Iceland, Liechtenstein and Norway
Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe
EC requires a post-authorization efficacy study and final results from the PREVAIL cardiovascular outcomes trial
Menarini milestone payments in the mid-teens of millions of euros triggered by the authorizations
Nasdaq notified Linkhome Holdings on September 18, 2026 that the company has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had received a deficiency notice on June 29, 2026 after its stock closed below $1.00 for 30 consecutive business days. Shareholders face no listing action from this matter, since the stock met the bid price test for 10 consecutive business days.
Nasdaq deficiency notice received June 29, 2026 after 30 consecutive business days below $1.00
Closing bid price was at least $1.00 for 10 consecutive business days, September 3 through September 17, 2026
Nasdaq notified the company on September 18, 2026 that compliance was regained and the matter is closed
Trilogy Metals said the U.S. Army Corps of Engineers has published a Notice of Intent to prepare an Environmental Impact Statement for its flagship Arctic Project in northwestern Alaska, formally starting the National Environmental Policy Act review and a public scoping phase. The company said the schedule still targets a draft EIS in October 2027 and a Record of Decision in September 2028, which shareholders may watch as the project's main federal permitting milestones.
Notice of Intent published by the U.S. Army Corps of Engineers, announced September 21, 2026, launching public scoping
Schedule continues to target a draft EIS in October 2027 and a Record of Decision in September 2028
Clean Water Act Section 404 permit application was filed by Ambler Metals on April 20, 2026
Arctic Project is advanced by Ambler Metals LLC, a 50/50 joint venture with South32
Credit Acceptance entered consent judgments dated September 17, 2026, with the attorneys general of 40 states and the District of Columbia. The agreements resolve a 2023 New York lawsuit and a multistate investigation, without any admission of wrongdoing. The company says the payments and debt relief will not require charges beyond amounts already accrued, but the judgments remain subject to court approval.
Company to pay $60 million to a trust for consumer loss remediation and $15.5 million to the participating attorneys general
Debt relief waives all outstanding balances for certain customers with open accounts as of December 1, 2025, estimated at $634,000,000
Five-year changes to debt-collection practices and seven-year disclosure, dealer oversight and other requirements; annual compliance reports for five years
Each agreement requires court approval in its jurisdiction, and the filing gives no assurance on approval or timing
Hyperfine received a Nasdaq notice on September 17, 2026, stating its Class A common stock has closed below $1.00 per share for 30 consecutive business days, so it no longer meets the minimum bid price requirement. The stock continues to trade on The Nasdaq Global Market under HYPR, but the company must regain compliance by March 16, 2027, or face possible delisting.
Nasdaq notice dated September 17, 2026 cites closing bid price below $1.00 for 30 consecutive business days
Compliance Date is March 16, 2027, requiring at least $1.00 closing bid for 10 consecutive business days
If not compliant by then, the company may be eligible for another 180 calendar days by transferring to The Nasdaq Capital Market
Failing cure could lead to delisting notice, with a possible appeal to a Nasdaq Hearings Panel
First Northwest Bancorp's subsidiary, First Fed Bank, agreed on September 15, 2026 to settle a lawsuit filed by Socotra REIT I, LLC, in exchange for a $1.3 million cash payment and dismissal of the complaint with prejudice. The company said resolving the dispute avoids the estimated costs and uncertainties of continued litigation, and the settlement does not admit liability.
Settlement Agreement & Mutual Release entered into on September 15, 2026
Bank to pay $1.3 million in cash within 30 days of the agreement
Complaint, filed October 17, 2025 in King County Superior Court, is to be dismissed with prejudice
Settlement is a compromise and does not constitute an admission of liability
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.